Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

061IC - Evaluation & Management of Urinary Tract Bleeding: From Asymptomatic Microhematuria to Intractable Hemorrhagic Cystitis

Monday, May 21
7:30 AM - 9:30 AM
Location: MCC WEST, 2008

Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria. Specifically, after attending the course, participants will understand the guideline recommendations for the initial evaluation of patients with asymptomatic microscopic hematuria, as well as the evidence supporting these recommendations. Recommendations for follow-up of these patients will also be covered. In addition, the course will cover the initial and follow-up evaluation for patients presenting with symptomatic microscopic hematuria and gross hematuria. The course will also include a practical, case-based presentation of frequently-encountered clinical management challenges, particularly for refractory hemorrhagic cystitis and persistent BPH-related bleeding. Detailed information will be provided regarding intravesical treatment regimens and associated side effect profiles. Additionally, data will be reviewed supporting treatments for refractory disease, including hyperbaric oxygen and selective angioembolization.

Learning Objectives:

Stephen A. Boorjian

Mayo Clinic

Dr. Stephen A. Boorjian is the Carl Rosen Professor of Urology, Vice Chair of Research for the Department of Urology, and the Director of the Urologic Oncology Fellowship at Mayo Clinic. He received his MD from Harvard Medical School, and was a resident in Urology at New York Presbyterian Hospital-Weill Cornell Medical Center. He subsequently completed a fellowship in Urologic Oncology at Mayo Clinic. Dr. Boorjian has co-authored over 300 manuscripts and book chapters, and was recognized as “Teacher of the Year” in Urology for 2012 by the Mayo Clinic Fellows’ Association. Moreover, he has twice won the Best Reviewer Award and once won the Outstanding Reviewer Award from the Journal of Urology, and has been awarded the Reviewer of the Month as well as Reviewer of the Year by European Urology, where he is now an Associate Editor. He was recognized with the 2014 Young Urologist of the Year award from the AUA and the 2016 Young Investigator Award from the Society of Urologic Oncology. He is a member of the NCCN Guidelines Panels for Bladder Cancer and Penile Cancer, and served on the AUA Non-Muscle Invasive Bladder Cancer Guidelines Panel. His research interests include optimizing the management for patients with high-risk prostate cancer, evaluating the outcomes among patients undergoing radical cystectomy for bladder cancer, and improving surgical therapy for advanced renal cell carcinoma.

Presentation(s):

Send Email for Stephen Boorjian

Daniel A. Barocas

Vanderbilt University Medical Center

Daniel A. Barocas, MD, MPH, FACS is Associate Professor of Urologic Oncologiy at the Vanderbilt University Medical Center, and the Vanderbilt Ingraham Cancer Center. He has clinical and research interests in urologic cancers, particularly in the detection and treatment of localized cancers, and the measurement of patient outcomes and quality of care. He is co-director of the Center for Surgical Quality and Outcomes research, an intellectual home for surgeon scientists at VUMC. Dr. Barocas has received grants from NIH to study active surveillance for prostate cancer care, and to study variation in the evaluation of hematuria. He is currently co-PI of the CEASAR study (Comparative Effectiveness Assessment of Surgery And Radiation), funded by AHRQ to study patient-reported outcomes in a large prospective, population-based cohort study. In addition to his activities as a urologic oncologist and health services researcher, Dr. Barocas is involved with national organizations, including the American Urological Association and Commission on Cancer, in development of quality measures for urologic cancer care.

Presentation(s):

Send Email for Daniel Barocas

Jay D. Raman

Penn State Health Milton S. Hershey Medical Center

Jay D. Raman, M.D. is currently Professor of Surgery and Chief of the Division of Urology at the Penn State Milton S. Hershey Medical Center in Hershey, PA. He received his undergraduate degree from MIT and graduated AOA from Cornell University Medical College. Dr. Raman completed his urology residency at Cornell Medical Center followed by a fellowship in minimally invasive surgery at the University of Texas Southwestern Medical Center.

Dr. Raman’s clinical practice focuses on robotic-assisted surgery for upper and lower tract urologic cancers as well as endourology. His basic science research centers on infectious complications following prostate needle biopsy, while his major clinical research efforts revolve around staging and therapy for upper-tract urothelial carcinoma. To date, he has co-authored over 230 manuscripts, book chapters, and editorials and serves as on the editorial board of 3 journals and a reviewer for an additional 10 journals.

Dr. Raman is currently Chair of the American Urologic Association (AUA) Video Education Committee, Course Director for the AUA Fundamentals of Urology Course, and is Secretary for the Mid-Atlantic section of the AUA. In 2015, he was named as a Young Urologist of the Year by the AUA for his clinical and scholarly activity.

Presentation(s):

Send Email for Jay Raman


Assets

061IC - Evaluation & Management of Urinary Tract Bleeding: From Asymptomatic Microhematuria to Intractable Hemorrhagic Cystitis



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Evaluation & Management of Urinary Tract Bleeding: From Asymptomatic Microhematuria to Intractable Hemorrhagic Cystitis